Interpat

Ideas
Protected for all

Interpat Innovation Seminar 2026 - Mexico City 8th -11th September 2026

Intellectual property in catalysing healthcare innovation. By exploring the intricate relationship between these realms, our objective is to foster ground-breaking discussions that raise healthcare standards and effectively address societal health dilemmas, particularly in Latin America. To delve deeper, we’re assembling industry and IP luminaries from the region to share insights and chart future strategies. This event promises 2 days of enlightening expert panels, dynamic interaction, and valuable networking. Esteemed judges, officials, academics and entrepreneurs across Latin America, leading in these fields, will grace the seminar. Simultaneous translation (English, Portuguese, Spanish) will be provided. Following a very successful seminar in Mexico City last year, we will be returning in September 2026 to continue the dialogue with representatives from the Latin American regions.

Interpat Innovation Seminar - Latin America

Dates to be announced shortly...

The biopharma Intellectual Property think tank

We’re Interpat: The biopharmaceutical think tank that supports policy makers and implementors to ensure that the ideas of the future can flourish. We do this by advocating for robust tried and tested Intellectual Property frameworks that deliver certainty and security.

Membership

We actively promote the transformational benefits of IP and its power to drive original thinking in the Life Sciences. We do this with our members, governments, intergovernmental bodies, NGOs and wider society and we work tirelessly to advocate for healthcare innovation around the world

Sharing expertise

Cross-industry support

Sustainable innovation

Supporting leaders

Reviewing best practice

Ideas incubator

Unprecedented: The Rapid Innovation Response to COVID-19 and the Role of IP

The COVID-19 pandemic presented humanity with unprecedented challenges. Researchers and biopharmaceutical companies responded by developing and delivering COVID-19 vaccines and treatments in record time. The innovation response to COVID-19 has been a singular achievement, but we will not be done until every person who needs a vaccine can get one.